FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200427979> ?p ?o ?g. }

• W4200427979 endingPage "39" @default.
• W4200427979 startingPage "37" @default.
• W4200427979 abstract "Langerhans cell histiocytosis (LCH) is an inflammatory, neoplastic disease, most commonly of toddlers and young children, that can present as a skin-limited disease or as a systemic disease with or without cutaneous manifestations.1Willman C.L. Busque L. Griffith B.B. et al.Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.N Engl J Med. 1994; 331: 154-160https://doi.org/10.1056/NEJM199407213310303Crossref PubMed Scopus (837) Google Scholar The pathogenetic basis of LCH is the accumulation of S100, CD1a, and langerin-positive (CD207+) dendritic cells. BRAF V600E mutations are found in 60% of the cases.1Willman C.L. Busque L. Griffith B.B. et al.Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.N Engl J Med. 1994; 331: 154-160https://doi.org/10.1056/NEJM199407213310303Crossref PubMed Scopus (837) Google Scholar,2Badalian-Very G. Vergilio J.A. Degar B.A. et al.Recurrent BRAF mutations in Langerhans cell histiocytosis.Blood. 2010; 116: 1919-1923https://doi.org/10.1182/blood-2010-04-279083Crossref PubMed Scopus (714) Google Scholar In both the skin-limited and systemic forms, LCH has a vast range of possible presentations.3Munn S. Chu A.C. Langerhans cell histiocytosis of the skin.Hematol Oncol Clin North Am. 1998; 12: 269-286https://doi.org/10.1016/s0889-8588(05)70510-4Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar Particularly with skin-limited LCH, the disease may spontaneously resolve, leading to underdiagnosis.4Lau L. Krafchik B. Trebo M.M. Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year.Pediatr Blood Cancer. 2006; 46: 66-71Crossref PubMed Scopus (73) Google Scholar While diagnosis of skin lesions of LCH has utility in detecting occult systemic LCH, which can be associated with significant morbidity, including acute lymphoblastic leukemia, the skin may be the only organ system involved.1Willman C.L. Busque L. Griffith B.B. et al.Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.N Engl J Med. 1994; 331: 154-160https://doi.org/10.1056/NEJM199407213310303Crossref PubMed Scopus (837) Google Scholar,5Ehrhardt M.J. Humphrey S.R. Kelly M.E. Chiu Y.E. Galbraith S.S. The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience.J Pediatr Hematol Oncol. 2014; 36: 613-616https://doi.org/10.1097/MPH.0000000000000248Crossref PubMed Scopus (17) Google Scholar,6Egeler R.M. Neglia J.P. Aricò M. Favara B.E. Heitger A. Nesbit M.E. Acute leukemia in association with Langerhans cell histiocytosis.Med Pediatr Oncol. 1994; 23: 81-85https://doi.org/10.1002/mpo.2950230204Crossref PubMed Scopus (76) Google Scholar In this report, we present a case of biopsy-confirmed LCH that initially presented as crusted papules in an acneiform distribution in a 15-year-old man. A 15-year-old man presented for initial dermatologic consultation with a chief complaint of acne. The patient and his mother were most concerned about a papule on the left nasal ala that had been growing over the past few months (Fig 1, A). They had more recently noticed smaller papules inferior to the initial lesion. The papule bled when scratched, but was otherwise asymptomatic (lacking pruritus and pain). Otherwise, the patient had a history of type 1 diabetes mellitus on insulin and a remote history of thrombocytopenia that had resolved by the time of the consultation. On physical exam, a 4-mm pink-red papule was observed on the left nasal ala, with a few smaller 1-2-mm papules surrounding the larger papule. Given the eroded clinical appearance that had not resolved over 2 months, the decision was made to biopsy the left nasal papule. Biopsy findings included sheets of histiocytes in the dermis (Fig 2). The histiocyte nuclei were folded, grooved, or kidney-bean shaped. Staining was positive with S-100, langerin, and CD1a, and partially positive with CD68. Despite the polypoid configuration of the lesion, the histopathologic findings were compatible with a lesion of LCH. The patient was initially advised to apply hydrocortisone 2.5% to the lesions. He was referred to hematology for further workup, which revealed no evidence of systemic involvement. Complete metabolic panel, complete blood count, ferritin, erythrocyte sedimentation rate, prothrombin time and international normalized ratio, and urine osmolality were all within the normal ranges. The positron emission tomography-computed tomography scan revealed no evidence of hypermetabolic mass or lymphadenopathy, and chest x-ray was similarly unremarkable. The nasal lesion regrew following biopsy (Fig 1, B), and the patient was instructed to start clobetasol 0.05% cream. At the 3-month follow-up visit, this lesion had completely resolved (Fig 1, C). However, the patient developed lesions of similar appearance on the left anterior aspect of the shoulder (Fig 1, D), upper portion of the back, and right nasal ala. He continues to be followed closely by hematology to ensure the lack of conversion to systemic LCH. We present a case of skin-limited LCH presenting as several pink-red papules distributed on the face, chest, and back of a 15-year-old man. The case is particularly unique given the patient's age at onset, color, and papular morphology, demonstrating the utility of a biopsy of persistent non-folliculocentric hemorrhagic papules and nodules. The presentation of LCH, whether skin-limited or systemic, is rare in patients over the age of 5, and most research regarding the disease involves the neonatal population.7Poompuen S. Chaiyarit J. Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study.Eur J Pediatr. 2019; 178: 771-776https://doi.org/10.1007/s00431-019-03356-1Crossref PubMed Scopus (8) Google Scholar In early infancy, vesicles and bullae are the most common manifestation, and LCH lesions may look similar to erythema toxicum or herpes simplex, conditions that are common in this population.8Haupt R. Minkov M. Astigarraga I. et al.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatr Blood Cancer. 2013; 60: 175-184https://doi.org/10.1002/pbc.24367Crossref PubMed Scopus (320) Google Scholar Later in infancy, seborrheic dermatitis-like lesions are the most common presentation, encompassing 42.8% of LCH presentations according to one study.7Poompuen S. Chaiyarit J. Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study.Eur J Pediatr. 2019; 178: 771-776https://doi.org/10.1007/s00431-019-03356-1Crossref PubMed Scopus (8) Google Scholar Few case reports of LCH in adolescents exist in the literature. Of note, a case of skin-limited LCH presenting as an erythematous plaque with a lichenified appearance was reported in a 16-year-old male.9McCarthy S. Quinlan C. Dvorakova V. Foley C. Murphy L.A. A case of a cutaneous folliculotropic Langerhans cell histiocytosis.J Am Acad Dermatol. 2016; 74: AB95Google Scholar Given the various presentations, LCH may pose a diagnostic dilemma in any age group. In our case, the patient's pink-red papular lesion was thought to be acne in an adolescent man by the family and patient's pediatrician. First-line management of skin-limited LCH involves watchful waiting, as lesions may spontaneously resolve, or treatment with topical corticosteroids.10Krooks J. Minkov M. Weatherall A.G. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up.J Am Acad Dermatol. 2018; 78: 1047-1056https://doi.org/10.1016/j.jaad.2017.05.060Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar It is imperative to establish a clear diagnosis of skin-limited versus systemic LCH at the time of diagnosis, as systemic LCH may involve significantly more morbidity. The most common manifestation of systemic LCH is the presence of bone lesions, and systemic LCH is classified as having “risk organ involvement” if the liver, spleen, or bone marrow is affected.8Haupt R. Minkov M. Astigarraga I. et al.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatr Blood Cancer. 2013; 60: 175-184https://doi.org/10.1002/pbc.24367Crossref PubMed Scopus (320) Google Scholar The recommended assessment at the time of diagnosis includes a thorough history and physical exam with focus on the skin, lymph nodes, bones, central nervous system, lungs, liver, and spleen, with basic laboratory tests (complete blood count, liver function tests, and complete metabolic panel) and assessment for endocrinopathy, such as growth hormone deficiency or diabetes insipidus.10Krooks J. Minkov M. Weatherall A.G. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up.J Am Acad Dermatol. 2018; 78: 1047-1056https://doi.org/10.1016/j.jaad.2017.05.060Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar Furthermore, routine monitoring is necessary for these patients, as there is a small risk of progression from skin-limited to systemic LCH.5Ehrhardt M.J. Humphrey S.R. Kelly M.E. Chiu Y.E. Galbraith S.S. The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience.J Pediatr Hematol Oncol. 2014; 36: 613-616https://doi.org/10.1097/MPH.0000000000000248Crossref PubMed Scopus (17) Google Scholar The recommended follow-up guidelines for patients with skin-limited LCH are for every 2-4 weeks with active lesions, and for every 6 months for 5 years following regression of skin lesions.10Krooks J. Minkov M. Weatherall A.G. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up.J Am Acad Dermatol. 2018; 78: 1047-1056https://doi.org/10.1016/j.jaad.2017.05.060Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar In summary, we present a unique case of skin-limited LCH in an adolescent man that initially presented as crusted papules in an acneiform distribution. Although LCH can be skin-limited and often is a benign disease, it is important to exclude internal involvement and monitor for any progression to systemic LCH over time. None disclosed." @default.
• W4200427979 created "2021-12-31" @default.
• W4200427979 creator A5014960791 @default.
• W4200427979 creator A5034294182 @default.
• W4200427979 creator A5038787161 @default.
• W4200427979 date "2022-02-01" @default.
• W4200427979 modified "2023-09-27" @default.
• W4200427979 title "Skin-limited Langerhans cell histiocytosis presenting as crusted papules in an acneiform distribution in an adolescent man" @default.
• W4200427979 cites W2048765718 @default.
• W4200427979 cites W2069035104 @default.
• W4200427979 cites W2078289340 @default.
• W4200427979 cites W2158332141 @default.
• W4200427979 cites W2161388714 @default.
• W4200427979 cites W2312341372 @default.
• W4200427979 cites W2325716909 @default.
• W4200427979 cites W2799471173 @default.
• W4200427979 cites W2919881475 @default.
• W4200427979 doi "https://doi.org/10.1016/j.jdcr.2021.11.024" @default.
• W4200427979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35036502" @default.
• W4200427979 hasPublicationYear "2022" @default.
• W4200427979 type Work @default.
• W4200427979 citedByCount "0" @default.
• W4200427979 crossrefType "journal-article" @default.
• W4200427979 hasAuthorship W4200427979A5014960791 @default.
• W4200427979 hasAuthorship W4200427979A5034294182 @default.
• W4200427979 hasAuthorship W4200427979A5038787161 @default.
• W4200427979 hasBestOaLocation W42004279793 @default.
• W4200427979 hasConcept C142724271 @default.
• W4200427979 hasConcept C16005928 @default.
• W4200427979 hasConcept C2777484599 @default.
• W4200427979 hasConcept C2779134260 @default.
• W4200427979 hasConcept C2780174970 @default.
• W4200427979 hasConcept C71924100 @default.
• W4200427979 hasConceptScore W4200427979C142724271 @default.
• W4200427979 hasConceptScore W4200427979C16005928 @default.
• W4200427979 hasConceptScore W4200427979C2777484599 @default.
• W4200427979 hasConceptScore W4200427979C2779134260 @default.
• W4200427979 hasConceptScore W4200427979C2780174970 @default.
• W4200427979 hasConceptScore W4200427979C71924100 @default.
• W4200427979 hasFunder F4320306204 @default.
• W4200427979 hasFunder F4320337738 @default.
• W4200427979 hasLocation W42004279791 @default.
• W4200427979 hasLocation W42004279792 @default.
• W4200427979 hasLocation W42004279793 @default.
• W4200427979 hasLocation W42004279794 @default.
• W4200427979 hasOpenAccess W4200427979 @default.
• W4200427979 hasPrimaryLocation W42004279791 @default.
• W4200427979 hasRelatedWork W146561991 @default.
• W4200427979 hasRelatedWork W1985053612 @default.
• W4200427979 hasRelatedWork W2063154210 @default.
• W4200427979 hasRelatedWork W2160493984 @default.
• W4200427979 hasRelatedWork W2562523974 @default.
• W4200427979 hasRelatedWork W2738981461 @default.
• W4200427979 hasRelatedWork W2795139703 @default.
• W4200427979 hasRelatedWork W2910726842 @default.
• W4200427979 hasRelatedWork W4234833016 @default.
• W4200427979 hasRelatedWork W4297184974 @default.
• W4200427979 hasVolume "20" @default.
• W4200427979 isParatext "false" @default.
• W4200427979 isRetracted "false" @default.
• W4200427979 workType "article" @default.